Akebia Therapeutics, Inc.
AKBA
Jodie situation report
Akebia Therapeutics, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 21 of 21 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
- At least 14 of 21 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as CBLL begins moving with the group.
Invalidation: The live read weakens if participation falls to 7 of 21 members or fewer.
Who this business touches
The relationships behind AKBA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AMGNAmgen Inc.competitorMay 7, 2026 ▾
“Vafseo Competition Drugs that compete with Vafseo include Epogen® (epoetin alfa) and Aranesp® (darbepoetin alfa), both commercialized by Amgen, Procrit® (epoetin alfa) and Eprex® (epoetin alfa), commercialized by Johnson & Johnson in the U.S.”
FMSFresenius Medical Care AGcompetitorMay 7, 2026 ▾
“Auryxia Competition Hyperphosphatemia Competition Auryxia is competing in the hyperphosphatemia market in the U.S.”
Depended on by
UNCYUnicycive Therapeutics, Inc.competitorMar 30, 2026 ▾
“Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the development and commercialization of oxylanthanum carbonate, and any other product or product candidate, including those that may be in-licensed…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 10 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AKBA is currently a Participant in the organic co-movement group Oncology and Gastrointestinal Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.